BBA
BBIO icon

Baader Bank Aktiengesellschaft’s BridgeBio Pharma BBIO Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,700
Closed -$1.05M – 432
2025
Q4 		$1.05M Buy
13,700
+1,175
+9% +$77.1K 0.07% 177
2025
Q3 		$650K Buy
+12,525
New +$611K 0.04% 238

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baader Bank Aktiengesellschaft's BBIO Position: Q1 2026 in Review

Baader Bank Aktiengesellschaft sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 13,700 shares — an estimated $1.05M sold.

Baader Bank Aktiengesellschaft first reported a position in BBIO in Q3 2025 and held it in 2 quarters. The position peaked at $1.05M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Baader Bank Aktiengesellschaft reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 13,700 BridgeBio Pharma shares in Q1 2026, an estimated $1.05M.
  • Baader Bank Aktiengesellschaft first reported a position in BridgeBio Pharma in Q3 2025 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's BridgeBio Pharma position peaked at $1.05M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2026, filed 8 May 2026.